Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

11.03 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amicus Therapeutics

Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) 
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.